Table 1.

Baseline characteristics by triglyceride group among all 9270 SHARP participants

CharacteristicAll ParticipantsTriglycerides (mg/dl)
<132.8 (n=2929)≥132.8 to <212.4 (n=2917)≥212.4 (n=3045)
Triglycerides, mg/dl169 (118–247)100 (81–118)167 (150–188)288 (244–376)
LDL cholesterol, mg/dl107 (34)96 (31)110 (33)115 (35)
Non-HDL cholesterol, mg/dl146 (43)122 (35)146 (37)168 (43)
HDL cholesterol, mg/dl43 (13)49 (14)43 (12)37 (10)
TRL cholesterol, mg/dl38 (18)26 (9)35 (11)53 (21)
TG/HDLc ratio1.77 (1.11–2.92)0.91 (0.67–1.19)1.75 (1.43–2.16)3.57 (2.70–5.00)
Apo-A1, mg/dl134 (29)139 (31)135 (28)128 (26)
Apo-B, mg/dl96 (26)84 (22)98 (23)107 (26)
Age at randomization, yr62 (12)62 (12)62 (12)61 (11)
Men5800 (63%)1830 (62%)1751 (60%)1965 (65%)
Prior vascular disease1393 (15%)378 (13%)492 (17%)475 (16%)
Diabetes2094 (23%)569 (19%)631 (22%)812 (27%)
Current smoker1234 (13%)377 (13%)385 (13%)422 (14%)
Diastolic BP, mm Hg79 (13)79 (13)79 (13)79 (13)
Systolic BP, mm Hg139 (22)139 (22)139 (22)138 (22)
Body mass index, kg/m227.1 (5.6)25.6 (5.3)27.0 (5.6)28.5 (5.5)
Albumin, g/l40.1 (3.7)39.6 (3.8)40.0 (3.8)40.7 (3.6)
C-reactive protein, mg/l3.0 (1.2–7.1)2.6 (0.9–6.8)3.0 (1.2–7.2)3.4 (1.5–7.1)
Troponin I, ng/ml0.01 (0.01–0.02)0.01 (0.01–0.02)0.01 (0.01–0.02)0.01 (0.01–0.02)
Ethnicity
 White6646 (72%)2034 (69%)2122 (73%)2228 (73%)
 Black264 (3%)130 (4%)62 (2%)43 (1%)
 Asian2086 (23%)678 (23%)652 (22%)685 (22%)
 Other/not specified274 (3%)87 (3%)81 (3%)89 (3%)
Comedication
 Antiplatelet therapy2105 (23%)654 (22%)682 (23%)690 (23%)
 ACE inhibitor or ARB5030 (54%)1492 (51%)1624 (56%)1746 (57%)
β-Blocker3514 (38%)938 (32%)1186 (41%)1261 (41%)
 Calcium channel blocker3840 (41%)1218 (42%)1268 (43%)1225 (40%)
Kidney status
 Not on dialysis6245 (67%)1957 (67%)1977 (68%)2092 (69%)
 On dialysis3025 (33%)972 (33%)940 (32%)953 (31%)
MDRD eGFR, ml/min per 1.73 m2a,b
 Mean (SD)26.6 (13.0)25.9 (13.2)26.3 (12.8)27.5 (13.0)
 ≥6088 (1%)27 (1%)24 (1%)37 (2%)
 ≥30 to <602155 (36%)679 (35%)703 (36%)773 (37%)
 ≥15 to <302565 (43%)773 (39%)847 (43%)945 (45%)
 <151219 (20%)478 (24%)403 (20%)337 (16%)
 Not available218000
Urinary albumin-to-creatinine ratio, mg/ga,b
 Median (IQR)206 (44–762)180 (38–696)198 (45–695)242 (48–916)
 <301107 (20%)384 (21%)361 (20%)358 (19%)
 ≥30 to ≤3002108 (38%)703 (39%)698 (38%)696 (36%)
 >3002357 (42%)715 (40%)757 (42%)879 (45%)
 Not available673155161159
  • Data are n (%), mean (SD), or median (IQR). SHARP, Study of Heart and Renal Protection; TRL, triglyceride-rich lipoprotein; TRL cholesterol, total cholesterol minus LDL cholesterol minus HDL cholesterol; TG/HDLc, triglyceride to HDL cholesterol ratio; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; MDRD, Modification of Diet in Renal Disease equation; IQR, interquartile range.

  • a Among patients not on dialysis.

  • b Percentages exclude participants for whom data were not available for that category.